Daniel B Ambrus1, Emelia J Benjamin2, Ednan K Bajwa3, Kathryn A Hibbert3, Allan J Walkey4. 1. Department of Internal Medicine, Section of Hospital Medicine, Umass Memorial Medical Center, 119 Belmont St, Worcester, MA, 01566; Department of Medicine, Division of General Internal Medicine, Boston University School of Medicine, 800 Massachusetts Ave, Boston, MA, USA. 2. Department of Medicine, Section of Cardiovascular Medicine and Preventive Medicine, Boston University School of Medicine, 88 East Concord St, Boston, MA 02118. 3. Department of Medicine, Pulmonary and Critical Care Unit, Massachusetts General Hospital, 55 Fruit St Boston MA. 4. Department of Medicine, Section of Pulmonary and Critical Care, The Pulmonary Center, Boston University School of Medicine, R-304, 72 East Concord St, Boston, MA, USA. Electronic address: alwalkey@bu.edu.
Abstract
PURPOSE: Outcomes and risk factors associated with new-onset atrial fibrillation (AF) during acute respiratory distress syndrome (ARDS) are unclear. We investigated mortality and risk factors associated with new-onset AF during ARDS. MATERIALS AND METHODS: We obtained data from the ARDS Network Albuterol for Treatment of Acute Lung Injury trial, which prospectively identified new-onset AF among patients with ARDS as an adverse event. We determined Acute Physiology and Chronic Health Evaluation III-adjusted associations between new-onset AF and 90-day mortality. We also examined associations between new-onset AF and markers of inflammation (interleukin 6 and interleukin 8), myocardial injury (troponin I), autonomic activation (epinephrine), and atrial stretch (central venous pressure) as well as other clinical characteristics. MEASUREMENTS AND MAIN RESULTS: Of 282 patients (mean age, 51.6 years; 45% women; 77% white) enrolled in Albuterol for Treatment of Acute Lung Injury, 28 (10%) developed new-onset AF during the study. We did not identify associations between new-onset AF and baseline central venous pressure, plasma levels of troponin I, epinephrine, interleukin 6, or interleukin 8. New-onset AF during ARDS was associated with increased 90-day mortality (new-onset AF, 43% vs no new-onset AF, 19%; Acute Physiology and Chronic Health Evaluation-adjusted odds ratio, 3.09 [95% confidence interval, 1.24-7.72]; P = .02). CONCLUSION: New-onset AF during ARDS is associated with increased mortality; however, its mechanisms require further study.
PURPOSE: Outcomes and risk factors associated with new-onset atrial fibrillation (AF) during acute respiratory distress syndrome (ARDS) are unclear. We investigated mortality and risk factors associated with new-onset AF during ARDS. MATERIALS AND METHODS: We obtained data from the ARDS Network Albuterol for Treatment of Acute Lung Injury trial, which prospectively identified new-onset AF among patients with ARDS as an adverse event. We determined Acute Physiology and Chronic Health Evaluation III-adjusted associations between new-onset AF and 90-day mortality. We also examined associations between new-onset AF and markers of inflammation (interleukin 6 and interleukin 8), myocardial injury (troponin I), autonomic activation (epinephrine), and atrial stretch (central venous pressure) as well as other clinical characteristics. MEASUREMENTS AND MAIN RESULTS: Of 282 patients (mean age, 51.6 years; 45% women; 77% white) enrolled in Albuterol for Treatment of Acute Lung Injury, 28 (10%) developed new-onset AF during the study. We did not identify associations between new-onset AF and baseline central venous pressure, plasma levels of troponin I, epinephrine, interleukin 6, or interleukin 8. New-onset AF during ARDS was associated with increased 90-day mortality (new-onset AF, 43% vs no new-onset AF, 19%; Acute Physiology and Chronic Health Evaluation-adjusted odds ratio, 3.09 [95% confidence interval, 1.24-7.72]; P = .02). CONCLUSION: New-onset AF during ARDS is associated with increased mortality; however, its mechanisms require further study.
Authors: Daniel De Backer; Patrick Biston; Jacques Devriendt; Christian Madl; Didier Chochrad; Cesar Aldecoa; Alexandre Brasseur; Pierre Defrance; Philippe Gottignies; Jean-Louis Vincent Journal: N Engl J Med Date: 2010-03-04 Impact factor: 91.245
Authors: Alanna M Chamberlain; Sunil K Agarwal; Aaron R Folsom; Elsayed Z Soliman; Lloyd E Chambless; Richard Crow; Marietta Ambrose; Alvaro Alonso Journal: Am J Cardiol Date: 2011-01 Impact factor: 2.778
Authors: Sangita-Ann Christian; Christa Schorr; Lynn Ferchau; Maria E Jarbrink; Joseph E Parrillo; David R Gerber Journal: J Crit Care Date: 2008-12 Impact factor: 3.425
Authors: Renate B Schnabel; Lisa M Sullivan; Daniel Levy; Michael J Pencina; Joseph M Massaro; Ralph B D'Agostino; Christopher Newton-Cheh; Jennifer F Yamamoto; Jared W Magnani; Thomas M Tadros; William B Kannel; Thomas J Wang; Patrick T Ellinor; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin Journal: Lancet Date: 2009-02-28 Impact factor: 79.321
Authors: Mik Wetterslev; Nicolai Haase; Christian Hassager; Emilie P Belley-Cote; William F McIntyre; Youzhong An; Jiawei Shen; Alexandre Biasi Cavalcanti; Fernando G Zampieri; Helio Penna Guimaraes; Anders Granholm; Anders Perner; Morten Hylander Møller Journal: Intensive Care Med Date: 2019-05-14 Impact factor: 17.440
Authors: Nicole Lowres; Graham S Hillis; Marc A Gladman; Mark Kol; Jim Rogers; Vincent Chow; Ferris Touma; Cara Barnes; Joanne Auston; Ben Freedman Journal: Int J Cardiol Heart Vasc Date: 2020-06-29
Authors: Olga Reynbakh; Eric D Braunstein; Mike Hsu; Jeff Ellis; Lori Crosson; Judith Lenane; Andrew Krumerman; Luigi Di Biase; Kevin J Ferrick Journal: Am Heart J Plus Date: 2022-01-10